VFVeronica Franco

Veronica Franco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Veronica Franco has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Suzanne Oparil

    From the Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama in Birmingham, Birmingham, Ala

    6 shared publications
  • Dajun Wang

    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham and

    2 shared publications
  • Gilbert Perry

    From the Vascular Biology and Hypertension Program (V.F., Y.-F.C., S.O., J.A.F., D.W., F.H., G.P.), Division of Cardiovascular Disease, University of Alabama at Birmingham, and the Cardiology Section (G.P.), Birmingham VA Medical Center, Birmingham, Ala

    2 shared publications
  • Ji An Feng

    From the Vascular Biology and Hypertension Program (V.F., Y.-F.C., S.O., J.A.F., D.W., F.H., G.P.), Division of Cardiovascular Disease, University of Alabama at Birmingham, and the Cardiology Section (G.P.), Birmingham VA Medical Center, Birmingham, Ala

    2 shared publications
  • Oscar A. Carretero

    From the Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham (V.F., S.O.), and the Hypertension and Vascular Research Division, Heart and Vascular Institute, Henry Ford Hospital, Detroit, Michigan (O.A.C.).

    2 shared publications
  • Andreas Knorr

    1 shared publication

Latest Publications

  • Is There a New Treatment for Hypertensive Disease in the Horizon?

    by Veronica Franco, Suzanne Oparil, Johannes-Peter Stasch, Pál Pacher, Oleg V. Evgenov, Michael Böhm, Claudia Gräbel, Markus Flesch, Andreas Knorr, Erland Erdmann, et al.


  • EPLERENONE PREVENTS ADVERSE CARDIAC REMODELLING INDUCED BY PRESSURE OVERLOAD IN ATRIAL NATRIURETIC PEPTIDE‐NULL MICE

    by Veronica Franco, Yiu‐Fai Chen, Ji A Feng, Peng Li, Dajun Wang, Erum Hasan, Suzanne Oparil, Gilbert J Perry

    SUMMARY: Atrial natriuretic peptide (ANP)‐null mice (Nppa‐/‐) exhibit cardiac hypertrophy at baseline and adverse cardiac remodelling in response to transverse aortic constriction (TAC)‐induced pressure overload stress. Previous studies have suggested that natriuretic peptides could potentially oppose mineralocorticoid signalling at several levels, including suppression of adrenal aldosterone production, inhibition of mineralocorticoid receptor (MR) activation or suppression of MR‐mediated production of pro‐inflammatory factors. Thus, we hypothesized that the MR blocker eplerenone would prevent the exaggerated left ventricular (LV) remodelling/fibrosis and dysfunction after TAC in Nppa‐/‐. In the present study, Nppa‐/‐ and wild‐type Nppa+/+ mice fed eplerenone‐ or vehicle (oatmeal)‐supplemented chow since weaning were subjected to TAC or sham operation. The daily dose of eplerenone administered was approximately 200 mg/kg. At 1 week after TAC, LV size and function were evaluated by echocardiogram and LV cross‐sections were stained with picrosirius red for collagen volume measurement. Total RNA was extracted from the LV for real‐time polymerase chain reaction analysis of osteopontin. Eplerenone had no effect on baseline hypertrophy observed in sham‐operated Nppa‐/‐ compared with Nppa+/+ mice. Eplerenone attenuated the TAC‐induced increase in LV weight in both genotypes and completely prevented LV dilation, systolic dysfunction and interstitial collagen deposition seen in Nppa‐/‐ mice after TAC. However, serum aldosterone levels were lower in Nppa‐/‐ compared with Nppa+/+ wild types. No interaction between eplerenone and genotype in osteopontin mRNA levels was observed. Eplerenone prevents adverse cardiac remodelling related to pressure overload in ANP‐deficient mice, mainly due to an antifibrotic effect. The mechanism whereby ANP deficiency leads to excess hypertrophy, fibrosis and early failure following TAC is increased profibrotic signals resulting from excess or unopposed MR activation, rather than increased levels of aldosterone.


  • Salt Sensitivity, a Determinant of Blood Pressure, Cardiovascular Disease and Survival

    by Veronica Franco, Suzanne Oparil

    High dietary sodium has been adduced as a cause of hypertension and its target organ damage for millennia; yet careful observations using sophisticated techniques have revealed only a weak relationship between sodium intake/excretion and blood pressure in the general population. Further, studies of the effects of dietary sodium reduction on blood pressure have revealed minimal achieved reductions in blood pressure, no relationship between the magnitude of reduction in sodium intake/excretion and the blood pressure effect, and no evidence of an effect of sodium reduction on death or cardiovascular events. While blood pressure in the population as a whole is only modestly responsive to alterations in sodium intake, some individuals manifest large blood pressure changes in response to acute or chronic salt depletion or repletion, and are termed “salt sensitive”. Salt sensitivity and resistance have a large variety of determinants, including genetic factors, race/ethnicity, age, body mass and diet (overall diet quality, macro- and micronutrient content), as well as associated disease states, e.g. hypertension, diabetes and renal dysfunction. Salt sensitivity can be modulated by improving the quality of the diet, e.g. the DASH diet reduced salt sensitivity by increasing the slope of the pressure-natriuresis curve. Mechanisms that appear to contribute to salt sensitivity include blunted activity of the renin-angiotensin-aldosterone system, deficiency in atrial natriuretic peptide expression, and blunted arterial baroreflex sensitivity. Salt sensitivity in both normotensive and hypertensive persons has been associated with increased cardiovascular disease events and reduced survival. Increased attention to strategies that reduce salt sensitivity, i.e. improvement in diet quality and weight loss, particularly in high risk persons, is urgently needed.


  • Atrial Natriuretic Peptide Dose-Dependently Inhibits Pressure Overload-Induced Cardiac Remodeling

    by Veronica Franco, Yiu-Fai Chen, Suzanne Oparil, Ji An Feng, Dajun Wang, Fadi Hage, Gilbert Perry

    We hypothesized that a single copy of the proatrial natriuretic peptide gene ( Nppa +/− ) would not be adequate to protect heterozygous mice against exaggerated cardiac hypertrophy and remodeling after pressure-overload stress. Nppa +/+ , Nppa +/− , and Nppa −/− mice were subjected to sham surgery or transverse aortic constriction and fed a basal salt diet. Heart weight varied inversely with Nppa gene load by 1 week after either surgery. Fractional shortening did not differ among genotypes at baseline and fell in Nppa −/− mice only after transverse aortic constriction. There was a graded response in collagen deposition related to atrial natriuretic peptide (ANP) expression after either surgery. A robust interstitial and perivascular fibrosis was noted in Nppa −/− and Nppa +/− but not in Nppa +/+ mice after transverse aortic constriction. Our findings are consistent with a growing body of evidence that ANP is an important modulator of cardiac hypertrophy and remodeling in response to hemodynamic stress. The observation that partial ANP deficiency results in exaggerated hypertrophy and remodeling after pressure overload suggests that genetic or environmental variation in ANP levels may play a role in the development of cardiac hypertrophy, remodeling, and failure in humans.


  • Hypertensive Therapy: Part II

    by Veronica Franco, Suzanne Oparil, Oscar A. Carretero

    If the incidence of hypertension in the population could be reduced through lifestyle modification, much of the morbidity and mortality associated with coronary heart disease, renal disease, and stroke might be prevented.1–3 Randomized, controlled trials have shown that lifestyle modification can lower blood pressure (BP) in both hypertensive and high-risk normotensive (now called prehypertensive ) persons and can prevent hypertension in the latter group. Accordingly, lifestyle modification is recommended for all persons (Table 1), either alone or in conjunction with pharmacological therapy (Table 21–34). View this table: TABLE 1. Lifestyle Modifications to Manage Hypertension *† View this table: TABLE 2. Guidelines for Treatment of Hypertension Based on Compelling Indications for Individual Drug Classes ### Weight Loss and Maintenance of Normal Body Weight Weight loss is the most effective of all nonpharmacological measures to prevent and treat hypertension.35 This effect is independent of sodium restriction and is seen in both obese and nonobese hypertensive individuals. Clinical trial evidence suggests that weight loss interventions produce BP benefits that persist even after cessation of active therapy.3,36 Body mass index (BMI) should be maintained between 18.5 and 24.9 kg/m2. Because sustained weight reduction is extremely difficult to achieve, emphasis should be placed on prevention of weight gain, particularly in younger individuals with prehypertension and in families with a high prevalence of hypertension. ### Increased Physical Activity At least 30 minutes of moderately intense physical activity, such as brisk walking, swimming, bicycling, or yard work, carried out at least 3 times per week (preferably once per day) can lower BP in both normotensive and hypertensive individuals. Studies suggest that such moderate activity may lower systolic BP (SBP) by 4 to 9 mm Hg.37,38 Additional benefits of regular physical activity include weight loss, enhanced sense of well-being, improved functional health status, and reduced risk of cardiovascular disease (CVD) and mortality from all causes. Accordingly, regular aerobic physical activity …


  • Hypertensive Therapy: Part I

    by Veronica Franco, Suzanne Oparil, Oscar A. Carretero


  • Open Access

    Atrial natriuretic peptide dose dependently inhibits cardiac remodeling after exposure to pressure overload

    by Veronica Franco, Yiu Fai Chen, Ji An Feng, Fadi Hage, Suzanne Oparil, Gilbert Perry

    We have previously shown that mice with homozygous deletion of the pro-atrial natriuretic peptide (ANP, Nppa−/−) gene exhibit left ventricular (LV) hypertrophy at baseline and exaggerated hypertrophy after pressure overload induced by transverse aortic constriction (TAC). Nppa−/− mice have increased expression of extracellular matrix molecules, i.e. metalloproteinase-2 and tissue inhibitor of metalloproteinase-3 and cardiac remodeling after TAC. A single copy of the pro-ANP gene (Nppa+/−) will not be adequate to protect heterozygous mice against exaggerated LV hypertrophy resulting from pressure overload stress. Therefore, Nppa+/− mice will have exaggerated cardiac remodeling compared to wild type Nppa+/+ mice after pressure overload stress. Cardiac remodeling in Nppa+/− mice will be less marked than in Nppa−/− animals. Nppa+/−, Nppa−/− and Nppa+/+ mice were subjected to TAC. Mice were fed a normal NaCl diet. One week after TAC, echocardiography was performed, hearts were removed and weighted. The heterozygote is a novel model for studying LV hypertrophy and the transition to failure during pressure overload stress. It is less abnormal than Nppa−/− at baseline and may more closely resemble the human condition. Am J Hypertens (2004) 17, 86A–87A; doi: 10.1016/j.amjhyper.2004.03.222